On October 9, 2025, the 2nd Jinfeng Stem Cell Forum and Stem Cell Transformation Research and Industrial Development Conference opened at the Chongqing Science Hall.

With the theme of "Quality Standards First, Promote High-Quality Development of the Stem Cell Industry", the conference is divided into opening ceremony, keynote report, sub-forums and closed-door meetings, and is hosted by Jinfeng Laboratory. The guiding units are Chongqing Municipal Science and Technology Bureau and the Western Science City Chongqing High-tech Zone Management Committee. The co-organizing unit is Beijing Zhaoyan New Drug Research Center Co., Ltd., and the cooperative units include Tianfu Jincheng Laboratory (Future Medical City), Industrial Bank Chongqing Branch, and Arterial Network.

The opening ceremony of the conference attracted more than 500 guests from the fields of government, industry, research, medicine, finance and law to gather together to discuss the path to quality standard construction, promote industrial transformation and high-quality development, and achieve important results.

Government perspective: Quality standard construction should be prioritized

The stem cell industry is at a critical stage of accelerating from scientific research breakthroughs to clinical transformation, and the establishment of stem cell quality standards is even more important and urgent.

Wang Li, deputy director of the Chongqing Municipal Food and Drug Administration, said that Chongqing is accelerating the creation of the "33618" modern manufacturing cluster system and the construction of the "416" scientific and technological innovation layout. The stem cell industry is both a key direction and an important support. As an emerging treatment technology, stem cell product quality is directly related to patient safety and sustainable development of the industry. The Municipal Food and Drug Administration will actively promote the formulation of quality standards, promote the construction of regional stem cell quality control and evaluation centers, strengthen the full-chain supervision system, and ensure that the stem cell industry develops steadily on a compliant, safe, and controllable track.

Jia Hui, a member of the Party Working Committee of the Chongqing High-tech Zone of the Western Science City and deputy director of the Management Committee of the Xiyong Comprehensive Bonded Zone, introduced that the Western (Chongqing) Science City has included the stem cell industry in the "15th Five-Year Plan" development plan, formulated special support policies, and created a pioneer demonstration zone for the development of the stem cell industry. Relying on high-energy platforms such as the Southwest Branch Center for Drug and Medical Device Review and Inspection of the State Food and Drug Administration and Jinfeng Laboratory, the Western (Chongqing) Science City will continue to make efforts in the formulation of quality standards, key technology research, and industrial ecological construction to promote the clustered development of the stem cell industry.

Expert opinion: The construction of quality standards needs to run through the entire process of scientific and technological innovation

The keynote report session explains the importance and implementation paths of quality standard construction in multiple dimensions.

Wang Songling, an academician of the Chinese Academy of Sciences, systematically introduced the research progress of mesenchymal stem cells in the treatment of various diseases, emphasizing that standardized preparation and quality control are the prerequisites for the clinical transformation of stem cells. It is urgent to establish a unified quality evaluation system and standardized operating procedures to ensure the consistency and repeatability of therapeutic effects.

Wu Zhaohui, Vice Chairman of the China Medical Biotechnology Association, reviewed the ten-year development of my country's stem cell clinical research registration system and pointed out that the continuous improvement of policy systems has pointed out the direction for industrial development. In the future, the coordinated construction of quality standards and regulatory systems should be further strengthened to promote stem cell products from "registration" to "marketing".

Hu Baoyang, executive director of the Institute of Stem Cell and Regenerative Medicine Innovation, Chinese Academy of Sciences, proposed from a strategic perspective that basic research and translational applications in the field of stem cells should be carried out in parallel, and the construction of quality standards should run through all aspects of scientific research, process development, and clinical verification to build a full-chain quality assurance system from source to end.

Dai Jianwu, executive director of the Institute of Biomedical Engineering of the Chinese Academy of Medical Sciences, gave a vivid explanation of the core position of stem cell technology in future precision medicine with the theme of "Regenerative Medicine Creates Human 4S Store" and called for the establishment of a unified, authoritative and operable quality standard system to promote the industrialization of stem cell technology.

Cooperation platform: The construction of quality standards will bring together the strengths of many parties

On the first day of the conference, a number of cooperation ceremonies were held to implement the collaborative mechanism for quality standard construction.

Wang Li, deputy director of Chongqing Medical Products Administration, and Xu Hui, deputy director of Jinfeng Laboratory, jointly unveiled the "Jinfeng Stem Cell Quality Control and Evaluation Center". The center will focus on the formulation of quality standards for stem cell products, the development of testing technology and the construction of service capabilities to create an authoritative platform for stem cell quality evaluation.

“"Jinfeng·Zhaoyan Joint Laboratory" was unveiled simultaneously. Jinfeng Laboratory and Zhaoyan New Drugs will carry out in-depth cooperation around the non-clinical and clinical evaluation of stem cell products, quality standard research and other aspects to promote the standardization and standardized development of stem cell drug research and development.

In addition, more than 10 units including Jinfeng Laboratory, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Stem Cells and Regenerative Medicine, the Second Affiliated Hospital of Chongqing Chongqing Medical University, Zhaoyan New Drug, Jiachang Biotech, Zehui Biotech, Saijun Biotech, Qianhui Technology, and Haijinge Pharmaceutical jointly initiated the establishment of the "Stem Cell Quality Standards and Application Innovation Complex". The complex is a national open collaborative innovation platform for stem cells. It aims to unite domestic universities, scientific research institutions, enterprises and other fields to jointly carry out stem cell quality standard research and technological method innovation, promote the formation of consensus and standards, and build a solid security defense line for the national stem cell industry.

On October 10, the conference will hold two sub-forums: "Progress in Clinical Research and Application of Stem Cells" and "Translation Road and Ecological Construction of Stem Cell Research". Experts and scholars from Sun Yat-sen University, Southern Medical University, Changping National Laboratory, Singapore Stem Cell Society and other institutions will conduct in-depth sharing and exchanges on topics such as new stem cell drug research and development, exosome therapy, nerve regeneration, legal supervision, investment trends and other topics.

The convening of the conference will promote China's stem cell industry to take solid steps in quality standard construction, cutting-edge technology transformation and industry coordinated development. At present and in the future, Jinfeng Laboratory will continue to work hard to actively build a new ecosystem for the stem cell industry with quality standards as the core, promote the deep integration of stem cell technological innovation and industrial innovation, cultivate new productive forces for the Chongqing stem cell industry, and contribute the "Golden Phoenix Power" to promote the high-quality development of my country's stem cell industry.